Clive Dix appointed to the Board of Precision Health Technologies Accelerator


Supporting innovation through University of Birmingham’s new flagship research facility

19 May 2022 We are proud to announce our Chief Executive officer, Dr Clive Dix BSc PhD HonFBPhS, has been appointed to the Board of the University of Birmingham’s flagship facility dedicated to translational health research – Precision Health Technologies Accelerator (“PHTA”).

Eva-Lotta Allan, Chairman of C4X Discovery, said: Clive’s appointment to the Board of PHTA is a reflection of his many accomplishments and clearly demonstrates the high regard in which he is held by all within the industry. PHTA is dedicated to showcasing British science at its best, driving innovation and providing access to cross-disciplinary expertise within a hub for collaboration across the industry. At C4XD, we know that Clive strives to promote great science and truly supports the people behind the science, for the benefit of patients. His vast knowledge and experience will be invaluable to PHTA as they look to create a thriving environment that allows science to deliver future life changing medicines.”

Clive Dix, CEO of C4X Discovery, added: “As a result of the pandemic, life science research has been thrust into the spotlight and, as novel technologies have been developed in months rather than years, it is important that we harness this momentum and continue the pace of innovation in biopharma and medtech. Birmingham, with PHTA as its new flagship facility, is poised to deliver everything that academics, start-ups and enterprises require to conceptualise, develop, validate and commercialise their innovations.”

The Precision Health Technologies Accelerator (PHTA) is the University of Birmingham’s signature health and life science research facility, providing approximately 70,000 sq ft of state-of-the-art laboratory, incubation and collaboration space and was supported with funding from GBSLEP. Working closely alongside Birmingham Health Partners, PHTA offers access to a wide range of expertise in clinical research, clinical trials and health data, as well as opportunities to work with key opinion leaders across the academic and clinical spectrum. Its physical facilities will include wet and dry research laboratories; prototype development and small-batch manufacturing; business incubation space and flexible hot-desking.

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

C4X Discovery Media – Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (“C4XD”) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.